FIRST QUARTER 2014 (JAN – MAR)
• Net sales in the quarter amounted to SEK 18.3 (16.3) million, corresponding to an increase of 12 percent in SEK. Sales increased by 10 percent in local currency.
• Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.1 (3.8) million, corresponding to an EBITDA margin of 17 percent.
• Net income amounted to SEK 1.8 (2.4) million, resulting in earnings per share of SEK 0.09 (0.12).
• Cash flow from operating activities was SEK -3.3 (4.0) million due to changes in trade payables that amounted to SEK -3.6 million and paid taxes that amounted to SEK -2.6 million.
• STEEN Solution™ and related products accounted for 24 (16) percent of total sales.
• The Advisory Panel convened by the FDA voted unanimously, by 10 votes to 0, that the XPS™ System with STEEN Solution™ meets the requirements for HDE (Humanitarian Device Exemption) approval.
• XPS™ (Xvivo Perfusion System) received a CE mark, allowing XPS™ and the accompanying single-use products to be sold in Europe.
• The first lung transplant in Turkey using a lung treated with the STEEN Solution™ method was performed at Sureyyapasa Teaching Hospital.
• Barnes Jewish Hospital in St. Louis, which is a pioneer in lung transplantation, will be the tenth transplant center to participate in the NOVEL trial. Organ Procurement Organization* (OPO) Mid-America Transplant Services in Missouri has bought an XPS™ to strengthen the collaboration between transplant centers and OPOs. The company plans to continue deploying XPS™ with recovery of costs, at transplant centers in the United States during the second quarter.
CONFERENCE CALL
CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, April 23, 2014. Telephone: +46 8 50336434, enter code 1319928
April 23, 2014
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO
** An OPO or Organ Procurement Organization is responsible for coordination and assessment of donated organs for organ transplantation in a region in the US.